The anti-aging drugs beta blockers are designed to prevent the onset of age-related disease and to slow or stop aging.
But the anti-ageing drugs beta-blockers are also being tested for their ability to slow the aging process in people who are already taking a drug to slow aging.
Now a new study from the University of Wisconsin, Madison finds that the anti—ageing drug beta-blocking drugs may also slow the progression of Alzheimer’s disease.
The study looked at the effectiveness of beta-agonist beta-agonists (also called beta-Blockers) in reducing the progression and survival of Alzheimer patients.
It was the first time that the researchers analyzed the effects of beta blocker beta- blockers on patients with Alzheimer’s.
“We found that when patients taking beta blockers were randomly assigned to either a placebo group or a beta-inhibitor group, the beta- blocker beta blockers significantly slowed the progression rate of Alzheimer disease compared with placebo,” said Dr. Ravi Gupta, the study’s lead author and an associate professor in the department of medicine and of pathology and pathology at UW Madison.
The results also suggested that the beta blocker drugs had an effect on the progression rates of Alzheimer, but only in the beta blockers group.
The researchers used a clinical trial with more than 3,000 people with Alzheimer disease, with all of the patients randomized to receive either beta-1-blocker beta-blocks (which block beta-protein-beta-1 receptors) or beta-2-blockER (which blocks beta-beta 2 receptors).
The researchers then followed the progression, survival, and the biomarkers of Alzheimer that were measured by a clinical biopsy.
The patients who were randomized to get beta blockers had better survival, a lower risk of dying from cardiovascular disease, and lower levels of biomarkers associated with Alzheimer.
The authors also found that beta blockers slowed the death rate of patients who had Alzheimer’s at the time of the clinical biopsies.
“Beta blockers may also be effective in treating Alzheimer patients who are taking older anti-oxidant therapies or in preventing the onset or progression of the disease,” the researchers wrote in the article.
The research was published online April 6 in JAMA Neurol.
The U.S. Food and Drug Administration (FDA) approved the beta Blockers for use in people over age 50 who have not yet reached the age of 100 years old.
The drug is being tested by drug companies to treat patients with advanced Alzheimer’s Disease and Alzheimer’s Related Dementia, which is also known as Alzheimer’s in the U.K. The FDA approved the anti beta blockers for use by people over 50 years old, and has said it expects to begin trials of the drug by the end of 2018.
The new study is the first to evaluate beta blocker Beta-block drugs for Alzheimer’s treatment in the trial, Gupta said.
The trial was conducted at the University College London in the United Kingdom.
The findings were based on data from the clinical trial.
Gupta and colleagues also published the results of a study that looked at beta blocker therapy in people with advanced HIV infection.
They found that patients taking a beta blocker had fewer signs and symptoms of HIV infection and fewer side effects than patients who did not take a beta block.
In a follow-up study, the researchers found that the drug had an additional benefit: a reduction in the rate of progression to advanced HIV-1 infection.
“The combination of these drugs may help people who have HIV-related dementia to delay the onset and progression of dementia,” Gupta said in a statement.
“In the future, we expect to see clinical trials in the future of the anti–aging drugs we are testing for Alzheimer.”